WANY
TOVX icon

Wealthspire Advisors (New York)’s Theriva Biologics TOVX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$1 – 2738
2025
Q3 		$1 Buy
+2
New +$1 ﹤0.01% 3060

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

Wealthspire Advisors (New York)'s TOVX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Theriva Biologics (TOVX) in Q4 2025, closing a stake of 2 shares — an estimated $1 sold.

Wealthspire Advisors (New York) first reported a position in TOVX in Q3 2025 and held it in 1 quarter. The position peaked at $1 in Q3 2025. 21 funds tracked by Wall St. Rank hold TOVX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Theriva Biologics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 2 Theriva Biologics shares in Q4 2025, an estimated $1.
  • Wealthspire Advisors (New York) first reported a position in Theriva Biologics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Theriva Biologics position peaked at $1 in Q3 2025.
  • 21 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.